|
Information For:
|
Notice of Correction to Ranitidine InjectionMarch 16, 2007An erratum correction was published in the First Supplement to USP30–NF25 but was incorrectly presented in the electronic versions. The Assay subsections in Ranitidine Injection were expanded from their original brief cross-references to Ranitidine Hydrochloride to present complete detailed procedures. This was necessary when the Assay in the drug substance monograph was revised and no longer applied to the related dosage form monographs. The erratum published in table form in First Supplement to USP30–NF25 states the correction properly, but the drug substance's newly revised Assay procedures were incorrectly inserted in the electronic file for Ranitidine Injection. We apologize for this error and provide here a corrected PDF of Ranitidine Injection What's NewChanges to the Dissolution Performance Verification Test (11/20/09) PF 35(6) Errata (10/30/09) New official Text for October: 15 Revisions Bulletins (10/30/09) Pending Standards for the month of October (10/30/09) PF 35(6), November-December 2009: Highlights and Stimuli Articles (10/23/09) Admission Criteria and Safety Classification for Dietary Supplements Guideline (10/22/09) Elemental Impurities Hot Topics information updated (10/13/09) General Chapter <1151> Pharmaceutical Dosage Forms (10/06/09) Heparin Hot Topics information updated (10/02/09)
Related Resources |
||||||||||||||||||||||||||||
Copyright © 2009 The United States Pharmacopeial Convention
|
|||||||||||||||||||||||||||||